MedTrace Logo

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

NCT04171284 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-02-09

No results posted yet for this study

Summary

This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients. The main endpoint is to compare the overall survival (OS) of these two regimens above.

Conditions

  • Squamous-cell Non-Small-cell Lung Cancer

Interventions

DRUG

SCT-I10

200 mg, Q3W, maximum treatment up to six cycles

DRUG

Docetaxel

70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles

DRUG

Placebo

200 mg, Q3W, maximum treatment up to six cycles

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Principal Investigators

  • Han Baohui, M.D. · Shanghai Chest Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2023-02-23
Completion
2023-02-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04171284 on ClinicalTrials.gov